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1. INTRODUCTION 
 
Aqueous solubility of any therapeutically active substance is a key property as it governs 
dissolution, absorption and thus the in vivo efficacy. Poorly water soluble compounds 
have solubility and dissolution related bioavailability problems. The dissolution rate is 
directly proportional to the solubility of drugs. Drugs with low aqueous solubility have 
low dissolution rates and hence suffer from oral bioavailability problems. The poor 
solubility and poor dissolution rate of poorly water soluble drugs in the aqueous gastro 
intestinal fluids often cause insufficient bioavailability. Other in-vivo consequences due 
to poor aqueous solubility include increased chances of food effect, more frequent 
incomplete drug release from the dosage form and higher inter-patient variability. 
   
Improvement in solubility of a poorly water soluble drug would increase gastrointestinal 
absorption of the drug thereby increasing the bioavailability which may result in 
reduction of dose. Further, this would also decrease food effect and inter-patient 
variability. In effect, this would result in improving the therapeutic efficacy and increase 
patient compliance. 
 
Nearly 40% 
1
 of the new chemical entities currently being discovered are poorly water 
soluble drugs. Thus, there is a greater need to develop a composition, which provides 
enhanced solubility of the poorly soluble drugs and increases its dissolution rate and thus 
improves its bioavailability to provide a formulation with reduced dose and better 
therapeutic efficacy and as a result overcomes the drawbacks presented by the prior art. 
 
Drugs which are having poor water solubility are etoposide, glyburide, itraconazole, 
ampelopsin, valdecoxib, celecoxib, halofantrine, tarazepide, atovaquone, amphotericin 
B, paclitaxel and bupravaquone etc. 
 
 
 
 
 
 
TECHNIQUES OF SOLUBILITY ENHANCEMENT 
2
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There are various techniques available to improve the solubility of poorly soluble drugs. 
They are: 
 
1. Physical Modification 
              A. Particle size reduction 
                         a. Micronization 
                         b.Nanosuspension 
              B. Modification of crystal habit 
                         a. Polymorphs 
                         b. Pseudopolymorphs 
              C. Drug dispersion in carriers 
                         a. Eutectic mixtures 
                         b. Solid dispersions 
             D. Complexation 
                         a. Use of complexing agents 
             E. Solubilization by surfactants: 
                         a. microemulsion 
                         b. Self microemulsifying drug delivery systems 
2. Chemical Modification 
3. Other techniques 
                         a. Hydrotrophy 
                         b. Solubilizing agent 
                         c. Nanotechnology approaches 
                         d. Liquisolid Technique 
I. Physical Modification 
20 
 
A. Particle size reduction: 
Particle size reduction can be achieved by micronisation and nanosuspension. Each 
technique utilizes different equipments for reduction of the particle size. 
i. Micronization 
The solubility of drug is often related to drug particle size. By reducing the particle size, 
the surface area gets increases which improve the dissolution properties of the drug. 
Conventional methods of particle size reduction, such as comminution and spray drying, 
rely upon mechanical stress to disaggregate the active compound. Micronization is not 
suitable for drugs having high dose number because it does not change the saturation 
solubility of the drug 
3
. 
ii. Nanosuspension: 
Nanosuspensions are sub-micron colloidal dispersion of pure particles of drug, which are 
stabilised by surfactants 
4
. The advantages offered by nanosuspension is increased 
dissolution rate due to larger surface area exposed, while absence of Ostwald ripening is 
due to the uniform and narrow particle size range obtained, which eliminates the 
concentration gradient factor. 
Techniques for the production of nanosuspension 
a.Homogenization 
The suspension is forced under pressure through a valve that has nano aperture. This 
causes bubbles of water to form which collapses as they come out of valves. This 
mechanism cracks the particles 
5
.  
Three types of homogenizers are commonly used for particle size reduction in the 
pharmaceutical and biotechnology industries: conventional homogenizers, sonicators, 
and high shear fluid processors.  
b. Wet milling:  
Active drug in the presence of surfactant is defragmented by milling.  
Other technique involves the spraying of a drug solution in a volatile organic solvent into 
a heated aqueous solution. Rapid solvent evaporation produces drug precipitation in the 
presence of surfactants.  
The nanosuspension approach has been employed for drugs including tarazepide, 
atovaquone, amphotericin B, paclitaxel and bupravaquone 
6
. All the formulations are in 
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the research stage. One major concern related to particle size reduction is the eventual 
conversion of the high-energy polymorph to a low energy crystalline form, which may 
not be therapeutically active one. Drying of nanosuspensions can be done by 
lyophilisation or spray drying. 
B. Modification of crystal habits 
Polymorphism is the ability of an element or compound to crystallize in more than one 
crystalline form. Different polymorphs of drugs are chemically identical, but they exhibit 
different physicochemical properties including solubility, melting point, density, texture, 
stability etc. Broadly polymorphs can be classified as enantiotropes and monotrophs 
based on thermodynamic properties. In the case of an enantiotropic system, one 
polymorph form can change reversibly into another at a definite transition temperature 
below the melting point, while no reversible transition is possible for monotrophs. Once 
the drug has been characterized under one of this category, further study involves the 
detection of metastable form of crystal. Metastable forms are associated with higher 
energy and thus higher solubility. Similarly the amorphous form of drug is always more 
suited than crystalline form due to higher energy associated and increase surface area.  
Generally, the anhydrous form of a drug has greater solubility than the hydrates. This is 
because the hydrates are already in interaction with water and therefore have less energy 
for crystal breakup in comparison to the anhydrates (i.e. thermodynamically higher 
energy state) for further interaction with water. On the other hand, the organic 
(nonaqueous) solvates have greater solubility than the nonsolvates.  
Some drugs can exist in amorphous form (i.e. having no internal crystal structure). Such 
drugs represent the highest energy state and can be considered as super cooled liquids. 
They have greater aqueous solubility than the crystalline forms because they require less 
energy to transfer a molecule into solvent. Thus, the order for dissolution of different 
solid forms of drug is  
Amorphous >Metastable polymorph >Stable polymorph  
Melting followed by a rapid cooling or recrystallization from different solvents can 
produce metastable forms of a drug.  
C.  Drug dispersion in carriers  
The term “solid dispersions” refers to the dispersion of one or more active ingredients in 
an inert carrier in a solid state, frequently prepared by the melting (fusion) method, 
solvent method, or fusion solvent-method 
7
. Novel additional preparation techniques 
have included rapid precipitation by freeze drying 
8
 and using supercritical fluids 
9
 and 
22 
 
spray drying 
10
, often in the presence of amorphous hydrophilic polymers and also using 
methods such as melt extrusion. The most commonly used hydrophilic carriers for solid 
dispersions include polyvinylpyrrolidone 
11
, polyethylene glycols 
12
, Plasdone-S630 
13
. 
Many times surfactants may be also used in the formation of solid dispersion. Surfactants 
like Tween-80, Docusate sodium, Myrj-52, Pluronic-F68 and Sodium Lauryl Sulphate 
were frequently used in this type of preparations..  
The solubility of etoposide 
14
, glyburide 
15
, itraconazole 
16
, ampelopsin 
17
, valdecoxib
18
, 
celecoxib 
19
, halofantrine 
20
 has been improved by solid dispersion using suitable 
hydrophilic carriers.  
The eutectic combination of chloramphenicol/urea 
21
 and sulphathiazole/ urea 
22
 served 
as examples for the preparation of a poorly soluble drug in a highly water soluble carrier.  
1. Hot Melt method 
In this method drug and carrier were melted together and then cooled in an ice bath. The 
resultant solid mass was then milled to reduce the particle size. Cooling leads to 
supersaturation, but due to solidification the dispersed drug becomes trapped within the 
carrier matrix. A molecular dispersion can be achieved or not, depends on the degree of 
supersaturation and rate of cooling used in the process 
23
. An important requisite for the 
formation of solid dispersion by the hot melt method is the miscibility of the drug and 
the carrier in the molten form. When there are miscibility gaps in the phase diagram, this 
usually leads to a product that is not molecularly dispersed. Another important requisite 
is the thermostability of the drug and carrier.  
2. Solvent Evaporation Method 
In this method both the drug and the carrier are dissolved in a common solvent and the 
solvent is evaporated under vacuum to produce a solid solution. This enabled to produce 
a solid solution of the highly lipophilic drug in the highly water soluble carrier. An 
important prerequisite for the manufacture of a solid dispersion using the solvent method 
is that both the drug and the carrier are sufficiently soluble in the solvent. The solvent 
can be removed by various methods like by spray-drying or by freeze-drying. 
Temperatures used for solvent evaporation generally lie in the range 23-65˚ C.  
The solid dispersion of the 5- lipoxygenase/cyclooxygenase inhibitor ER-34122 showed 
improved in vitro dissolution rate compared to the crystalline drug substance which was 
prepared by solvent evaporation. These techniques have problems such as negative 
effects of the solvents on the environment and high cost of production due to extra 
facility for removal of solvents 
24
. 
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Due to the toxicity potential of organic solvents employed in the solvent evaporation 
method, hot melt extrusion method is preferred in preparing solid solutions.  
3. Hot-melt Extrusion 
Melt extrusion was used as a manufacturing tool in the pharmaceutical industry as early 
as 1971 
25
. It has been reported that melt extrusion of miscible components results in 
amorphous solid solution formation, whereas extrusion of an immiscible component 
leads to amorphous drug dispersed in crystalline excipient. The process has been useful 
in the preparation of solid dispersions in a single step.  
D. Complexation 
Complexation is the association between two or more molecules to form a nonbonded 
entity with a well defined stoichiometry. Complexation relies on relatively weak forces 
such as London forces, hydrogen bonding and hydrophobic interactions. There are many 
types of complexing agents and a partial list can be found in below table.  
Table: 1 List of Complexing Agents 
26
 : 
S.No Chemical class Examples 
1. Inorganic IB
-
 
2. Chelates EDTA 
3. Inclusion Cyclodextin(CD) 
 
Factors affecting complexation 
27
: 
1. Steric effects  
2. Electronic effects  
a. Effect of proximity of charge to CD cavity  
b. Effect of charge density  
c. Effect of charge state of CD and drug  
3. Temperature, additives and cosolvent effects 
 
E. Solubilization by surfactants 
Surfactants are molecules with distinct polar and nonpolar regions. Most surfactants 
consist of a hydrocarbon segment connected to a polar group. The polar group can be 
anionic, cationic, zwitterionic or nonionic. When small apolar molecules are added they 
can accumulate in the hydrophobic core of the micelles. This process of solubilization is 
very important in industrial and biological processes. The presence of surfactants may 
lower the surface tension and increase the solubility of the drug within an organic solvent 
28
.  
a.Microemulsion 
24 
 
A microemulsion is a four-component system composed of external phase, internal 
phase, surfactant and cosurfactant. The addition of surfactant, which is predominately 
soluble in the internal phase unlike the cosurfactant, results in the formation of an 
optically clear, isotropic, thermodynamically stable emulsion. It is termed as 
microemulsion because of the internal or dispersed phase is < 0.1 μ droplet diameter. The 
formation of microemulsion is spontaneous and does not involve the input of external 
energy as in case of coarse emulsions. The surfactant and the cosurfactant alternate each 
other and form a mixed film at the interface, which contributes to the stability of the 
microemulsions
29
. Non-ionic surfactants, such as Tweens (polysorbates) and Labrafil 
(polyoxyethylated oleic glycerides), with high hyrophile-lipophile balances are often 
used to ensure immediate formation of oil-in-water droplets during production.  
Advantages of microemulsion over coarse emulsion include its ease of preparation due to 
spontaneous formation, thermodynamic stability, transparent and elegant appearance, 
increased drug loading, enhanced penetration through the biological membranes, 
increased bioavailability 
30
, and less inter- and intra-individual variability in drug 
pharmacokinetics.  
II. Chemical Modifications:- 
For organic solutes that are ionizable, changing the pH of the system may be simplest 
and most effective means of increasing aqueous solubility. Under the proper conditions, 
the solubility of an ionizable drug can increase exponentially by adjusting the pH of the 
solution. A drug that can be efficiently solubilized by pH control should be either weak 
acid with a low pKa or a weak base with a high pKa. Similar to the lack of effect of heat 
on the solubility of non-polar substances, there is little effect of pH on nonionizable 
substances. Nonionizable, hydrophobic substances can have improved solubility by 
changing the dielectric constant (a ratio of the capacitance of one material to a reference 
standard) of the solvent by the use of co-solvents rather than the pH of the solvent.  
The use of salt forms is a well known technique to enhanced dissolution profiles. Salt 
formation is the most common and effective method of increasing solubility and 
dissolution rates of acidic and basic drugs
31
.An alkaloid base is, generally, slightly 
soluble in water, but if the pH of medium is reduced by addition of acid, and the 
solubility of the base is increased as the pH continues to be reduced. The reason for this 
increase in solubility is that the base is converted to a salt, which is relatively soluble in 
water (e.g. Tribasic calcium phosphate).The solubility of slightly soluble acid increased 
25 
 
as the pH is increased by addition of alkali, the reason being that a salt is formed (e.g. 
Aspirin, Theophylline, Barbiturates). 
III. Other techniques: 
1. Hydrotrophy: 
Hydrotrophy designate the increase in solubility in water due to the presence of large 
amount of additives. The mechanism by which it improves solubility is more closely 
related to complexation involving a weak interaction between the hydrotrophic agents 
(sodium benzoate, sodium acetate, sodium alginate, and urea) and the solute 
32
.  
Example: Solubilisation of Theophylline with sodium acetate and sodium alginate  
2. Solubilizing agents: 
The solubility of poorly soluble drug can also be improved by various solubilizing 
materials. PEG 400 is used for improving the solubility of hydrochlorthiazide
33
. 
Modified gum karaya , a recently developed excipient was evaluated as carrier for 
dissolution enhancement of poorly soluble drug, nimodipine
31
. The aqueous solubility of 
the antimalarial agent halofantrine is increased by the addition of caffeine and 
nicotinamide 
34
.  
3. Nanotechnology approaches: 
Nanotechnology will be used to improve drugs that have poor solubility. 
Nanotechnology refers broadly to the study and use of materials and structures at the 
nanoscale level of approximately 100 nanometers (nm) or less. For many new chemical 
entities of very low solubility, oral bioavailability enhancement by micronisation is not 
sufficient because micronized product has the tendency of agglomeration, which leads to 
decreased effective surface area for dissolution and the next step taken was Nanonisation 
35
. 
4. Liquisolid technique: 
36
 
With the liquisolid technology, a liquid may be transformed into a free flowing, readily 
compressible and apparently dry powder by simple physical blending with selected 
excipients named the carrier and coating material. The liquid portion, which can be a 
liquid drug, a drug suspension or a drug solution in suitable non-volatile liquid vehicles, 
is incorporated into the porous carrier material (Fig. 1). Once the carrier is saturated with 
liquid, a liquid layer is formed on the particle surface which is instantly adsorbed by the 
fine coating particles. Thus, an apparently dry, free flowing, and compressible powder is 
obtained. Usually, microcrystalline cellulose is used as carrier material and amorphous 
silicon dioxide (colloidal silica) as coating material. Various excipients such as 
26 
 
lubricants and disintegrants may be added to the liquisolid system to produce liquisolid 
compacts (Fig 2). 
Liquisolid compacts of poorly soluble drugs containing a drug solution or drug 
suspension in a solubilising vehicle show enhanced drug release due to an increased 
surface area of drug available for release, an increased aqueous solubility of the drug, 
and an improved wettability of the drug particles. Accordingly, this improved drug 
release may result in a higher drug absorption in the gastrointestinal tract and thus, an 
improved oral bioavailability. 
 
 
Fig 1: Schematic representation of liquisolid system 
 
 
 
Fig 2: Schemaic outline of steps involved in the preparation of liquisolid compacts 
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THEORY OF LIQUISOLID SYSTEMS 
 A powder can retain only limited amounts of liquid while maintaining acceptable flow 
and compression properties. To calculate the required amounts of powder excipients 
(carrier and coating materials) a mathematical approach for the formulation of liquisolid 
systems has been developed by Spireas 
37. This approach is based on the flowable (Ф-
value) and compressible (Ψ-number) liquid retention potential introducing constants for 
each powder/liquid combination. 
 
The Ф-value of a powder represents the maximum amount of a given non-volatile liquid 
that can be retained inside its bulk [w/w] while maintaining an acceptable flowability. 
The flowability may be determined from the powder flow or by measurement of the 
angle of repose. The Ψ-number of a powder is defined as the maximum amount of liquid 
the powder can retain inside its bulk [w/w] while maintaining acceptable compactability 
resulting in compacts of sufficient hardness with no liquid leaking out during 
compression. The compactability may be determined by the so-called “pactisity” which 
describes the maximum (plateau) crushing strength of a one-gram tablet compacted at 
sufficiently high compression forces. The terms “acceptable flow and compression 
properties” imply the desired and thus preselected flow and compaction properties which 
must be met by the final liquisolid formulation. 
 
Depending on the excipient ratio (R) of the powder substrate an acceptably flowing and 
compressible liquisolid system can be obtained only if a maximum liquid load on the 
carrier material is not exceeded. This liquid/carrier ratio is termed “liquid load factor Lf 
[w/w] and is defined as the weight ratio of the liquid formulation (W) and the carrier 
material (Q) in the system: 
 Lf = W/Q------ (1)  
 
R represents the ratio between the weights of the carrier (Q) and the coating (q) material 
present in the formulation: 
 
 R =Q/q------ (2) 
 
The liquid load factor that ensures acceptable flowability (Lf ) can be determined by: 
Lf =Φ+ φ. (1/R) ----- (3) 
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Where Φ and φ are the Ф-values of the carrier and coating material, respectively. 
Similarly, the liquid load factor for production of liquisolid systems with acceptable 
compactability (ΨLf) can be determined by: 
 
Lf = Ψ+ Ψ. (1/R) ------- (4) 
 
Where Ψ and ψ are the Ψ-numbers of the carrier and coating material, respectively. In 
Table 1 examples of liquisolid formulation parameters of various powder excipients with 
commonly used liquid vehicles. 
 
MECHANISMS OF ENHANCED DRUG RELEASE FROM LIQUISOLID 
SYSTEMS 
Several mechanisms of enhanced drug release have been postulated for liquisolid 
systems. The three main suggested mechanisms include an increased surface area of drug 
available for release, an increased aqueous solubility of the drug, and an improved 
wettability of the drug particles
43 .
 Formation of a complex between the drug and 
excipients or any changes in crystallinity of the drug could be ruled out using DSC and 
XRPD measurements.  
a. Increased drug surface  
If the drug within the liquisolid system is completely dissolved in the liquid vehicle it is 
located in the powder substrate still in a solubilized, molecularly dispersed state. 
Therefore, the surface area of drug available for release is much greater than that of drug 
particles within directly compressed tablets. 
 
b. Increased aqueous solubility of the drug 
In addition to the first mechanism of drug release enhancement it is expected that  the 
solubility of the drug, might be increased with liquisolid systems. In fact, the relatively 
small amount of liquid vehicle in a liquisolid compact is not sufficient to increase the 
overall solubility of the drug in the aqueous dissolution medium. However, at the 
solid/liquid interface between an individual liquisolid primary particle and the release 
medium it is possible that in this microenvironment the amount of liquid vehicle 
diffusing out of a single liquisolid particle together with the drug molecules might be 
sufficient to increase the aqueous solubility of the drug if the liquid vehicle acts as a 
cosolvent. 
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c. Improved wetting properties 
Due to the fact that the liquid vehicle can either act as surface active agent or has a low 
surface tension, wetting of the liquisolid primary particles is improved. Wettability of 
these systems has been demonstrated by measurement of contact angles and water rising 
times. 
 
OPTIMIZATION OF LIQUISOLID FORMULATIONS WITH ENHANCED 
DRUG RELEASE 
 
The liquisolid technology has been successfully applied to low dose, poorly water 
soluble drugs. The formulation of a high dose, poorly soluble drug is one of the 
limitations of the liquisolid technology. As the release rates are directly proportional to 
the fraction of molecularly dispersed drug (FM) in the liquid formulation a higher drug 
dose requires higher liquid amounts for a desired release profile. Moreover, to obtain 
liquisolid systems with acceptable flowability and compactability high levels of carrier 
and coating materials are needed. However, this results in an increase in tablet weight 
ultimately leading to tablet sizes which are difficult to swallow. Therefore, to overcome 
this and various other problems of the liquisolid technology several formulation 
parameters may be optimized. 
 
Table 2: Optimization of formulation parameters for liquisolid systems with 
immediate Drug release 
 
Formulation 
parameters 
Optimization Effects 
Liquid vehicle High drug solubility in the 
vehicle 
Increased fraction of the 
molecularly dispersed 
drug 
Carrier and coating 
material 
High specific surface area Increased liquid load 
factor 
Addition of excipients polyvinylpyrrolidine Increased liquid load 
factor 
Increased viscosity of 
liquid vehicle 
Excipient ratio High R value Fast disintegration 
Inhibition of precipitation 
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ADVANTAGES OF LIQUISOLID SYSTEMS 
37
: 
• Number of water-insoluble solid drugs can be formulated into liquisolid systems. 
• Can be applied to formulate liquid medications such as oily liquid drugs. 
• Better availability of an orally administered water insoluble drug. 
• Lower production cost than that of soft gelatin capsules 
• Production of liquisolid systems is similar to that of conventional tablets. 
• Can be used for formulation of liquid oily drugs 
• Exhibits enhanced in-vitro and in-vivo drug release as compared to commercial 
counterparts, including soft gelatin capsule preparations. 
• Can be used in controlled drug delivery. 
• Drug release can be modified using suitable formulation ingredients 
• Drug can be molecularly dispersed in the formulation. 
• Capability of industrial production is also possible. 
• Enhanced bioavailability can be obtained as compared to conventional tablets. 
 
LIMITATIONS: 
• Low drug loading capacities. 
• Requirement of high solubility of drug in non-volatile liquid vehicles. 
 
APPLICATIONS: 
• Rapid release rates are obtained in liquisolid formulations 
• These can be efficiently used for water insoluble solid drugs or liquid lipophilic 
drugs. 
• Sustained release of drugs which are water soluble drugs such as propranolol 
hydrochloride has been obtained by the use of this technique. 
• Solubility and dissolution enhancement. 
• Designing of controlled release tablets. 
• Application in probiotics. 
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2. REVIEW OF LITERATURE 
Sanjeevgubbi et.al 
38
 formulated and evaluated liquisolid compacts of Bromhexine 
Hydrochloride using  Avicel PH 102, Aerosil 200 and Explotab. The in vitro dissolution 
property of slightly water soluble Bromhexine hydrochloride (BXH) was improved by 
exploring the potential of Liquisolid system (LS). The interaction between drug and 
excipients in prepared LS compacts were studied by differential scanning calorimetry 
(DSC) and X- ray powder diffraction (XRPD). The drug release rates of LS compacts 
were distinctly higher as compared to directly compressed tablets, which show 
significant benefit of LS in increasing wetting properties and surface area of drug 
available for dissolution. The DSC and XRD studies confirms  no significant interaction 
between the drug and excipients used in LS compacts.  
 
Majid Saeedi et.al 
39
 developed liquisolid system of indomethacin. They showed that 
the liquisolid formulations exhibited significantly higher drug dissolution rates in 
comparison with directly compressed tablet. The enhanced rate of indomethacin 
dissolution derived from liquisolid tablets was probably due to an increase in wetting 
properties and surface area of drug particles available for dissolution. Moreover, it was 
indicated that the fraction of molecularly dispersed drug (FM) in the liquid medication of 
liquisolid systems was directly proportional to their indomethacin dissolution rate (DR). 
An attempt was made to correlate the percentage drug dissolved in 10 min with the 
solubility of indomethacin in PEG 200 and glycerin.  
 
Khalid M. El-Say et.al 
40
 prepared and characterised liquisolid compacts of Rofecoxib. 
The effect of powder substrate composition on the flowability and compressibility of 
liquisolid compacts were evaluated. Specifically, several liquisolid formulations, 
containing 25-mg Rofecoxib, which containing different carrier to coating ratios in their 
powder substrates and a fixed liquid medication, were prepared. The dissolution profiles 
of Rofecoxib liquisolid tablets were determined according to USP method. The obtained 
dissolution profiles were compared to that of a commercial product. The formulated 
liquisolid systems exhibited acceptable flowability and compressibility. In addition, 
liquisolid tablets displayed significant enhancement of the dissolution profiles compared 
to that of commercial one. 
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Indrajeet D. Gonjari et.al 
41
 formulated and evaluated sustained release liquisolid 
compact formulations of tramadol hydrochloride. Comparison of dissolution profiles of 
prepared compacts with marketed preparation was also done. Liquisolid sustained release 
formulations were prepared by using HPMC K4M as adjuvant for sustaining release. The 
prepared liquisolid compacts are new dosage forms showing more sustained release 
behavior as compared to marketed sustained formulations. Two Way ANOVA results 
showed significant difference in dissolution profiles. This systematic approach to the 
formulation was found to be useful in analyzing sustained release of tramadol 
hydrochloride. The application and evaluation of model dependent methods are more 
complicated. These methods give acceptable model approach which is indication of true 
relationship between percent drug release and time variables, including statistical 
assumptions.  
 
Y. Javadzadeh  et. al 
42
  studied the dissolution rate of piroxicam using liquisolid 
compacts .  In this study several liquisolid tablets formulations containing various ratios 
of drug:Tween 80 (ranging from 10% to 50% w/w) were prepared. The ratio of 
microcrystalline cellulose (carrier) to silica (coating powder material) was kept constant 
in all formulations. The results showed that liquisolid compacts demonstrated 
significantly higher drug release rates than those of conventionally made (capsules and 
directly compressed tablets containing micronized piroxicam). This was due to an 
increase in wetting properties and surface of drug available for dissolution. 
 
Spiro Spireas 
43
 prepared liquisolid compacts of prednisolone to enhance its dissolution 
rate.The in-vitro release characteristics of prednisolone were studied at different 
dissolution conditions. Liquisolid compacts demonstrated significantly higher drug 
release rates, in different dissolution media and volumes, compared to tablets prepared 
by the direct compression method. It was also observed that the drug dissolution rate 
from liquisolid tablets was independent of the volume of dissolution medium, in contrast 
to the plain tablets which exhibited declining drug release patterns with decreasing 
dissolution volumes. 
 
Amrit B. Karmarkar 
44
 formulated and evaluated liquisolid compacts of Fenofibrate 
using different ratio of carrier and drug concentration.The purpose of present study was 
to improve fenofibrate dissolution through its formulation into liquisolid tablets and then 
to investigate in vitro performance of prepared liquisolid systems. X-ray powder 
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diffraction and Differential Scanning Calorimetry were used for evaluation of 
physicochemical properties of Fenofibrate in liquisolid tablets. Stereomicroscopy was 
used to assess morphological characteristics of liquisolid formulation. Enhanced drug 
release profiles due to increased wetting properties and surface of drug available for 
dissolution was obtained in case of liquisolid tablets. 
 
Sanjeev Raghavendra Gubbi 
45
 formulated and characterised Atorvastatin liquisolid 
compacts.The ATR liquisolid compacts were prepared using Avicel PH 102 and Aerosil 
200 as the carrier and coating material, respectively. XRD studies showed complete 
inhibition of crystallinity in the ATR liquisolid compacts. It is transformed into an 
amorphous form which has the highest energy and solubility. The DSC study confirmed 
the absence of any interaction between the drug and excipients used in the preparation of 
ATR liquisolid compacts. The in vitro dissolution study confirmed enhanced drug 
release from liquisolid compacts compared with directly compressed counterparts and 
this was independent of the type and volume of the dissolution medium.  The liquisolid 
compacts showed an improvement in bioavailability compared with their directly 
compressed counterparts. It was observed that aging had no significant effect on the 
hardness, disintegration time and dissolution profile of the liquisolid compacts. 
 
Hitendra S. Mahajan et.al 
46
formulated and evaluated liquisolid compacts of Glipizide 
using treated Gellan gum as the disintegrant.This study aims to prepare immediate 
release glipizide liquisolid tablets using Avicel PH-102 and Aerosil 200 as the carrier 
and coating material respectively to increase dissolution rate of poorly soluble glipizide. 
They also evaluated treated Gellan gum as disintegrant in the preparation of liquisolid 
tablets.  The results obtained shows that all glipizide liquisolid tablets exhibits higher 
dissolution rates than those of marketed glipizide tablets. Dissolution rates increases with 
increasing concentration of liquid vehicles and maximum drug release achieved by 
formulations containing Polyethylene glycol 400 (PEG 400) as a liquid vehicle. The 
results of XRD and thermal analysis did not show any changes in crystallinity of drug 
and interaction between glipizide and excipients during the formulation process. 
 
Ali Nokhodchi et. al 
47
developed Liquisolid Theophylline to sustain the drug release 
from matrix compacts. Liquisolid tablets were prepared by mixing liquid medication 
with silica–Eudragit RL or RS followed by the compaction of the mixture. The 
interaction between excipients and theophylline was investigated by differential scanning 
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calorimetry. Comparison study of physicomechnanical properties of liquisolid tablets 
with conventional tablets showed that most of liquisolid formulations had superior 
flowability and compactibility in comparison with physical mixtures. The results 
suggested that the presence of non-volatile cosolvent is vital to produce slow release 
pattern for some of liquisolid compacts. The type of cosolvent had significant effect on 
drug release and it was revealed that by changing the type of cosolvent the desirable 
release profile is achievable. The sustained release action of HPMC was enhanced in 
liquisolid compacts in comparison to simple sustained release matrix tablets.  
 
Yousef Javadzadeh et . al 
48
 studied the effect of  liquisolid technique in reducing the 
dissolution rate  and thereby producing a sustained release systems. In the present study, 
propranolol hydrochloride was dispersed in polysorbate 80 as the liquid vehicle. Then a 
binary mixture of carrier–coating materials (Eudragit RL or RS as the carrier and silica 
as the coating material)was added to the liquid medication under continuous mixing in a 
mortar. Propranolol HCl tablets prepared by liquisolid technique showed greater 
retardation properties in comparison with conventional matrix tablets. This investigation 
provided evidence that polysorbate 80 (Tween 80) has important role in sustaining the 
release of drug from liquisolid matrices. X-ray crystallography and DSC ruled out any 
changes in crystallinity or complex formation during the manufacturing process of 
liquisolid formulations. 
 
Veerareddy et.al 
49
 formulated and evaluated liquisolid compacts of meloxicam. 
Dissolution efficiency, mean dissolution time and relative dissolution rate of liquisolid 
compacts were calculated and compared to marketed formulation. The degree of 
interaction between the Meloxicam and excipients was studied by differential scanning 
calorimetry and X-ray diffraction were used and results revealed that, there was a loss of 
meloxicam crystallanity upon liquisolid formulation and almost molecularly dispersed 
state, which contributed to the enhanced drug dissolution properties. The optimized 
liquisolid compact showed higher dissolution rates and dissolution efficiency compared 
to commercial product.  
 
Amal A. Elkordy et .al 
50
 studied the improvement in dissolution rate of Furosemide 
using Liquisolid technique. Several liquisolid tablets were prepared using 
microcrystalline cellulose (Avicel® pH-101) and fumed silica (Cab-O-Sil® M-5) as the 
carrier and coating materials, respectively. Polyoxyethylene- polyoxypropylene-
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polyoxyethylene block copolymer (Synperonic® PE/L 81); 1, 2, 3-propanetriol, 
homopolymer, (9Z)-9-octadecenoate (Caprol® PGE-860) and polyethylene glycol 400 
(PEG 400) were used as non- volatile water-miscible liquid vehicles.  The ratio of carrier 
to coating material was kept constant in all formulations at 20 to 1.  The        in-vitro 
release characteristics of the drug from tablets formulated by direct compression (as 
reference) and liquisolid technique, were studied in two different dissolution media. 
Differential scanning calorimetry (DSC) and Fourier Transform infrared spectroscopy 
(FT-IR) were performed.The results showed that all formulations exhibited higher 
percentage of drug dissolved in water (pH 6.4–6.6) compared to that at acidic medium 
(pH 1.2). Liquisolid compacts containing Synperonic® PE/L 81 demonstrated higher 
release rate at the different pH values. Formulations with PEG 400 displayed lower drug 
release rate, compared to conventional and liquisolid tablets Caprol® PGE-860, as a 
liquid vehicle, failed to produce furosemide liquisolid compacts. 
 
Amal A. Elkordy 
51
 formulated Liquisolid tablets of naproxen and evaluated the effects 
of different formulation variables, i.e. type of non-volatile liquid vehicles and drug 
concentrations, on drug dissolution rates. The liquisolid tablets were formulated with 
three different liquid vehicles, namely Cremophor EL , Synperonic PE/L61, and poly 
ethylene glycol 400 at two drug concentrations, 20%w/w and 40%w/w. Avicel PH102 
was used as a carrier material, Cab-o-sil M-5 as a coating material and maize starch as a 
disintegrant. It was found that liquisolid tablets formulated with Cremophor EL at drug 
concentration of 20%w/w produced high dissolution profile with acceptable tablet 
properties. The stability studies showed that the dissolution profiles of liquisolid tablets 
prepared with Cremophor EL were not affected by ageing significantly. Furthermore, 
DSC revealed that drug particles in liquisolid formulations were completely solubilised. 
 
A. V. Yadav et al 
52
 formulated and evaluated orodispersible liquisolid compacts of 
aceclofenac by using different dissolution enhancers and studied the effect of way of 
addition of superdisintegrants on rate dissolution of aceclofenac. Liquisolid compacts of 
aceclofenac were prepared by dispersing the drug in various dissolution enhancing 
agents(Propylene glycol, Polyethylene glycol 400 and Tween 80 in 1:1 ratio with  drug ), 
then addition of diluents, superdisintegratns (like Cross carmelose Sodium, Cross 
povidone and Sodium starch glycolate) in various ways and in combinations finally with 
the addition of glidants and lubricants. All liquisolid compacts being orodispersible 
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rapidly disintegrated within 3 minutes with enhanced dissolution properties over the 
conventional tablet of aceclofenac. Among all formulations, Tween 80 liquisolid 
compact containing cross carmelose sodium showed highest dissolution.  
Spireas et al 
53
studied the effect of powder substrate composition on the dissolution 
properties of methyclothiazide, a practically insoluble diuretic agent, as the model drug. 
Liquisolid tablets of methyclothiazide containing a 5% w/w drug solution in 
polyethylene glycol 400 were prepared using powder substrates of different carrier: 
coating ratios in their powder substrates from 5 to 70. Dissolution study showed 
enhanced cumulative release. 
 
El-Adawy 
54
 formulated nifedipine, a practically insoluble antianginal agent, in 
liquisolid tablets. Several liquisolid, 10 mg, tablet formulations containing different 
carrier/coat ratios in their powder substrate and different liquid medication of nifedipine 
in PEG 600, or Tween 80 was prepared. Avicel PH 200 and Cab-O-Sil were used as 
carrier and coating material, respectively, in different ratios and a standard 5% w/w of 
the disintegrant sodium starch glycolate (Explotab®) was added in all systems. The 
study showed enhanced dissolution rate when compared to conventional tablet. 
 
Nokhodchi et al 
55
 used the technique of liquisolid compacts to formulate and enhance 
the in-vitro release of piroxicam, which was formulated into 10mg liquisolid tablets 
consisting of similar powder excipients and Tween 80 with different drug concentrations 
in their liquid medications.They have also  utilized the liquisolid technique to increase 
dissolution rate of indomethacin and studied the effect of type and concentration of 
vehicles on the dissolution rate of a poorly soluble drug, indomethacin, from liquisolid 
compacts. 
 
From the above literature survey it was understood that liquisolid system is a promising 
method for improving the solubility of poorly soluble drugs. So in this present study 
liquisolid technique is used as a method for improving the solubility, and thereby the 
dissolution rate of Glibenclamide, which is a poorly soluble drug. 
 
 
 
39 
 
 
 
3. AIM AND OBJECTIVE 
 
Glibenclamide is an antidiabetic drug which belongs to the class sulfonyl ureas. It is 
poorly water soluble and hence have less oral bioavailability of about 40%. Since 
Glibenclamide is a poorly soluble drug it is classified under class II drugs as per BCS 
classification. Solubility plays a vital role in determining the invitro absorption of the 
drug, and hence the problem of poor solubility needs to be addressed with great care in 
formulating poorly soluble drugs.  Among the various method adopted to increase the 
solubility of drugs, liquisolid technique seems to be a promising technology. 
 
 The aim and objective of the study was to improve the solubility and dissolution 
characteristics of Glibenclamide using liquisolid technology. 
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4. PLAN OF WORK 
 
1. Preformulation studies 
2. Preparation of Liquisolid powder  
3. Preparation of tablet by direct compression method 
4. Evaluation test 
a. Hardness 
b. Friability 
c. Weight variation 
d. Assay 
e. Disintegration test 
f. Dissolution studies 
g. X-Ray Diffraction 
h. DSC Analysis 
5. Stability  study 
 
 
 
  
43 
 
5. DRUG PROFILE 
GLIBENCLAMIDE
56
 
Chemical IUPAC name: 1-[[4-[2-[(5-Chloro-2-methoxybenzoyl) amino] ethyl]                      
phenyl] sulphonyl-3-cyclohexyl urea. 
Empirical Formula: C23H28ClN3O5S 
Structural formula: 
 
Description: white or almost white, crystalline powder. 
Bioavailability: 42% 
Half Life          : 24hrs 
Mechanism of Action: 
Glibenclamide exerts pancreatic and extrapancreatic actions. It stimulates an increase in 
insulin release by the pancreatic β-cells. It may also reduce hepatic gluconeogenesis and 
glycogenolysis. Increased glucose uptake in the liver and utilization in the skeletal 
muscles. 
Absorption: Readily absorbed from the GI tract (oral); peak plasma concentrations after 
2-4 hr. 
Distribution:Protein-binding:Extensive. 
 
Metabolism:Hepatic; converted to very weakly active metabolite . 
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Excretion   : Urine (50%); faeces (50%). 
Dose and administration: 
Administered by oral route 
Dose                   : 5-10 mg 
Maximum dose  : 15mg in 24 hr 
 
 
 
 
 
  
45 
 
6. MICROCRYSTALLINE CELLULOSE
57
 
1. Structural formula     : 
 
 
2. Nonproprietary name        :            
 BP                                : Microcrystalline cellulose 
 JP                                 : Microcrystalline cellulose 
 PhEur                           : Cellulosum microcrystallinum 
 USPNF                         : Microcrystalline cellulose 
 
3. Synonym                             : Avicel ; Cellulose gel ; tabulose 
                                                   Crystalline cellulose; E460; Emcocel 
                                                   Fibrocel;vivacel                                                            
4. Chemical name                   : Cellulose 
5. Empirical formula              : (c6H10O5)n  
6. Molecular   weight              : ≈36000 where n≈220. 
7. Functional category            : Adsorbent;suspending agent;                             
             capsule and tablet diluents; tablet disintegrant.  
8. Physical state                      : It is a purified, partially depolymerised   
Cellulose that occurs white odourless, 
Tasteless,crystalline powder composed of porous 
particles.It is commercially available in different 
particle size and moisture grades which have different 
properties and applications. 
9. Typical properties                    :           
                  Density (bulk)             :        0.337 g/cm
3
 
                  Density (tapped)         :        0.478 g/cm
3
 
                  Density (true)              :        1.512-1.668 g/cm
3
 
                  Melting point              :        Chars at 260-270
o
C 
                  Moisture content         :        Less than 5% w/w 
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 10. Solubility                                :      Slightly soluble in   5%w/v    sodium  
Hydroxide solution,Practically  insoluble in 
water,dilute acids, and most                 Organic 
solvents. 
 11. Stability and storage condition:       
Microcrystalline     cellulose is a stable,though hygroscopic material.The bulk 
material should be stored in in a well closed container in a cool,dry,place.  
 12. Incompatibilities                    :         Incompatible with strong Oxidizing agents. 
13. Applications:            
It is widely used in pharmaceuticals, primarily as a binder/ diluents in oral tablet and 
capsule formulations.Where it is used in both wet granulation and direct compression 
processes. Microcrystalline cellulose also has some lubricant and disintegrant properties 
that make it useful in tableting.It is also used in cosmetics and food products. 
                    
                         
 
 
 
COLLOIDAL SILICON DIOXIDE
58
 
 
1.Structural formula   :         Sio2 
2.Non-proprietary  name  : 
 BP   :       Colloidal anhydrous silica 
 PhEur   :       silica colloidalis anhydrica 
 USP   :       Colloidal silicon dioxide 
3.Synonyms    :       Aerosil, fumed silica, cab-o-sil, colloidal  
silica,  silica anhydride, silicon dioxide 
fumed, wacker HDK 
4.Chemical name   : Silica 
5.Empirical formula   : Sio2 
6.Molecular weight   : 60.08 
7.Functional category  : Adsorbent, anticaking agent, glidant,  
suspen ding agent, tablet disintegrant, 
viscosity increasing agent. 
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8.Physical state   : It is a light, loose, bluish-white  
coloured,odourless, tasteless, nongritty 
amorphous powder. 
9.Typical properties   :  
         Density(bulk)  :     0.029-0.042 g/cm
3
 
         pH    :    3.5-4.4 (4% w/v aqueous      dispersion) 
10.Stability & storage condition :    It is hygroscopic, but absorbs large  
quantities of water without liquefying. It 
should be stored in a well-closed container. 
11.Incompatibilities   :    Incompatible with diethyl stilbesterol   
preparations. 
12.Applications :  
Colloidal silicon dioxide is widely used in pharmaceutical formulations to 
improve the flow properties of dry powders. The concentration of silicon dioxide used as 
glidant is 0.1-0.5%. It is also used in cosmetics and food products.         
 
CROS CARMELLOSE SODIUM 
 
1.Structural formula            : 
 
 
    
 
    
 
 
 
 
2. Non-proprietary name   :      
 BP   :          Croscarmellose sodium 
 JPE   :          Croscarmellose sodium 
 USP   :          Croscarmellose sodium 
3. Synonym   : Ac-Di-Sol, Solutab, Primellose, Pharmacel Xl 
4. Chemical name  :      Cellulose, carboxy methyl ether,  
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5. Molecular weight  : 90,000-7,00,000. 
6. Physical state  : Croscarmellose sodium occurs as an odourless,  
white coloured powder. 
7.Functional category : Tablet and capsule disintegrant 
8. Typical properties  : 
          Density(bulk)  :       0.529 g/cm
3
 
          Density(tapped) :       0.819 g/cm
3
 
          Density(true)  :       1.543 g/cm
3
 
9.Solubility   : Insoluble in water, rapidly swells to 4-8 times of  
its original volume on contact with water. 
10. Stability & storage condition:  
Croscarmellose sodium is a stable though hygroscopic material. It should be 
stored in a well-closed container in a cool, dry place. 
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11. Incompatibilities:  
The efficacy of croscarmellose sodium , may be slightly reduced in tablet 
formulations prepared by either wet granulation or direct compression process which 
contains hygroscopic excipients such as sorbitol. 
 
12. Applications:   
Croscarmellose sodium is used in oral pharmaceutical formulations as a 
disintegrant for tablet, capsules and granules. In tablet formulations, croscarmellose 
sodium may be used in both direct compression and wet granulation processes. 
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PROPYLENE GLYCOL
59
 
 
Structural formula: 
                        
                                        
Nonproprietary names : BP:Propylene glycol,PhEur:Propylenglycolum. 
Synonyms                        : 1,2-Dihydroxypropane;2-hydroxypropanol;  
propane-1,2-diol. 
Chemical name               : 1,2-Propanediol. 
Empirical  formula and  
molecular weight   : C3H8O2 ,76.1 
Functional category   : Antimicrobial preservative, disinfectant,  
humectant, stabilizer for vitamins. 
Incompatibilities  : Propylene glycol is incompatible with oxidizing  
reagents such as potassium permanganate. 
Solubility   : Miscible with acetone, chloroform,  
ethanol(95%),glycerin and water;soluble 1in 6 parts 
of ether;not miscible with light mineral oil or fixed 
oils,but will dissolve some essential oils. 
Typical properties  : Density: 1.038 g/cm
3
 at 20◦C. 
Applications: 
Propylene glycol has become widely used as a solvent,extractant,and preservative in a 
variety of parenteral and non-parenteral pharmaceutical formulations.It is commonly 
used as a plastizer in aqueous film-coating formulations 
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7. MATERIALS AND METHODS 
Table 3:   Instruments used 
INSTRUMENTS 
SUPPLIER/ MANUFACTURER 
 
Single pan analytical balance 
Amandi , Mumbai 
 
    Tablet punching machine 
Rimek 12, Ahmedabad 
 
Hardness tester 
Campbell electronics –Mumbai 
 
Roche  friabilator 
Campbell electronics –Mumbai 
 
Dissolution apparatus 
Campbell electronics –Mumbai 
 
Disintegration apparatus 
Campbell electronics –Mumbai 
 
UV spectrophotometer 
Schimadzu 
 
  
Table 4: Materials used 
MATERIAL SUPPLIER/ MANUFACTURER 
Glibenclamide Capplin point , pondicherry 
Propylene Glycol Nice chemicals pvt .ltd,kerala 
MCC Mitutiyo,india 
Aerosil FMC Biopolymer,Ireland 
Sodium starch glycolate Ascot pharmachem Pvt Ltd,Gujarat 
Cros carmellose sodium DME Fonterra Excipients,USA 
Magnesium stearate Parag  Fine Organics,Mumbai  
Talc CP  Kelco US Inc. USA 
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METHODOLOGY 
1. DETERMINATION OF λmax: 
Absorption spectra of Glibenclamide 
a) Stock solution of 1mg/ml of Glibenclamide was prepared by dissolving 
100mg of a drug in small quantity of methanol and sonicated for few minutes 
and diluted with phosphate buffer (pH 7.4). 
b) The stock solution was serially diluted to get solutions in the range of 2-
10µg/ml and λmax of the solution was found out by scanning the solution from 
200-400 nm using UV-VS spectrometer. 
c) The λ max of the solution was found to be 227 nm. 
2. DETERMINATION OF STANDARD CURVE: 
a) Stock solution of 1000μg/ml of Glibenclamide was prepared by dissolving 
10mg of drug in small quantity of methanol and sonicated for few minutes 
and diluted with methanol to 10ml. 
b) From this take 1 ml and make up to 10 ml using methanol to get a stock 
solution of 100 μg/ml. 
c) From the above solution take 5ml and dilute to 50 ml using phosphate buffer 
to get a stock solution of 10 μg/ml. 
d) The stock solution was serially diluted to get solutions in the range of 2- 
10μg/ml λ max of the solution was found out. 
e) The absorbance of the different diluted solutions was measured in a UV 
spectrophotometer at 227nm. 
f) A calibration curve was plotted by taking concentration of the solution in µg 
on X-axis and absorbance on Y-axis and correlation co-efficient “r” was 
calculated. 
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3. DETERMINATION OF SOLUBILITY 
Solubility studies of glibenclamide were carried out in water, Propylene Glycol, 
Polyethylene Glycol 400, and Tween 80. Saturated solutions were prepared by adding 
excess drug to the vehicles and shaking on the shaker for 48 h at 25 ± 0.5°C under 
constant vibration. After this period the solutions were filtered, diluted and analyzed by 
UV-spectrophotometer at 227 nm. 
4. FORMULATION OF LIQUISOLID SYSTEM 
 
1. Calculated quantities of Glibenclamide and propylene glycol was accurately 
weighed and mixed thoroughly in a motar to produce the drug solution. 
2. Quantities of carrier and coating materials required were calculated based on „R‟ 
value and were added into the drug solution and mixed thoroughly. 
3. Mixing process is carried out in three steps :  
a. During first stage powder was blended for approximately one minute so 
that the liquid medication will equally distribute in the powder. 
b. In second stage, mixture was evenly spread as a uniform layer on the 
surfaces of mortar and left standing for approximately 5 min to allow 
drug solution to be absorbed in the interior of powder particles. 
c. In third stage, powder was scraped off the mortar surfaces by means of 
aluminum spatula and then blended with 5% super disintegrant (CCS), 
2%magnesium stearate & 1 % talc for another 30 seconds in a similar to 
first stage. This gives final formulation of liquisolid tablets. 
         
Conventional tablet of pure drug was also prepared by direct compression 
technique to compare its release rate with that of liquisolid compacts. 
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Table 5: Formulation chart of liquisolid tablets 
 
Formulation Drug 
concentration in 
PG 
(%w/w) 
Excipient Ratio 
(R) 
 
Liquid Load 
Factor (Lf) 
LS-1 5 10 0.491 
LS-2 5 20 0.325 
LS-3 5 30 0.270 
LS-4 10 10 0.491 
LS-5 10 20 0.325 
LS-6 10 30 0.270 
LS-7 15 10 0.491 
LS-8 15 20 0.325 
LS-9 15 30 0.270 
LS-10 20 10 0.491 
LS-11 20 20 0.325 
LS-12 20 30 0.270 
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5. EVALUATION OF POWDER BLEND 
Preformulation study is the characterization of the physiochemical parameters of the 
drug substance by the application of biopharmaceutical principles with the goal of 
designing an optimum drug delivery system. The characterization of drug and the drug - 
excipient compatibility information decides most of the subsequent events and 
approaches in development of the formulation. Preformulation study involves the 
physiochemical characterization of the drug, solubility determination of the drug, 
determination of the drug-excipient compatibility, development of the analytical methods 
and the stability studies. 
The prepared powder blend were subjected to evaluation as per the methods suggested in 
the Indian Pharmacopoeia like Angle of repose, Bulk density, Tap density, 
Compressibility index, Hausner‟s ratio.  
a) Angle of repose 
60
:      
The angle of repose is the maximum angle which is formed between the surface of a pile 
of powder and horizontal surface. It is determined by the funnel method. A funnel was 
kept vertically at a specified height and the funnel bottom was closed. 10 gm of sample 
powder was filled inside the funnel. Then funnel was opened to release the powder to 
form a smooth conical heap which just touches the tip of the funnel. From the powder 
cone, the radius of the heap (r) and the height of the heap (h) were measured. The angle 
of repose is represented as „θ‟ and is calculated using the following equation: 
 
 Tan θ = h/r    …….. (5)                                     
           Where,     h = Height of the pile 
            θ = Tan -1 h/r     r = Radius of the pile 
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Table 6:  Flow properties and corresponding Angles of repose 
 
FLOW PROPERTY ANGLE OF REPOSE (DEGREES) 
Excellent 25-30 
Good  31-35 
Fair  36-40 
Passable 41-45 
Poor  46-55 
Very poor  56-65 
Very, very poor >66 
 
b) Bulk density 
61
: 
The bulk densities of the samples were determined by transferring the accurately 
weighed sample of powder to the graduated 50 ml measuring cylinder. The initial 
volume (bulk volume) and weight was noted. The bulk density is calculated by the 
formula: 
Bulk Density = Weight of Sample / Bulk Volume …..(6)   
c) Tapped density 
61
:  
An accurately weighed powder sample was transferred to the graduated 50ml measuring 
cylinder and was placed on the tap density test apparatus. The apparatus was operated for 
a fixed number of taps. The final volume (tap volume) of the tapped massed was noted. 
The tapped density was calculated by using the formula: 
Tapped Density = Weight of Sample/ Tapped Volume …… (7)       
d) Compressibility index: 
The bulk density, cohesiveness of the material, surface area, size and shape and 
the moisture content influences the Compressibility index. The compressibility index is 
determined from the bulk volume and tap volume. The basic method used for the 
determination of compressibility index is to measure the bulk volume and the final 
tapped volume after a fixed number of tapping until no change in volume occurs. It is 
represented in percentage. 
% Compressibility = (Tapped density - Bulk density) / Tapped density X 100 ……. 
(8)       
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Table 7: Scale of Flowability based on Compressibility Index 
COMPRESSIBILITY 
INDEX (%) 
FLOW 
CHARACTER 
≤10 Excellent  
11-15 Good  
16-20 Fair  
21-25 Passable  
26-31 Poor  
32-37 Very poor 
>38 Very, very poor  
 
e) Hausner’s ratio:  
Hausner‟s ratio is the ratio of the initial volume of the powder mass to the final 
volume of the powder mass obtained after the specified number of tapping 
                         Table 8: Scale of Flowability based on Hausner’s Ratio 
 
 
 
 
 
 
 
 
 
 
f) Assay of Blend 
Powder was weighed equivalent to 10 mg Glibenclamide  and transfer to 100ml 
volumetric flask. Add few ml of methanol and sonicated for 10min.Then filter the 
solution through whatmann filter paper and made up to 100ml with phosphate buffer (pH 
7.4). 1ml of resultant solution was taken and diluted to 100ml with phosphate buffer (pH 
7.4) and the absorbance was measured at 227nm by UV spectrophotometer. 
 
 
 
HAUSNER’S RATIO FLOW CHARACTER 
1-1.11 Excellent  
1.12-1.18 Good  
1.19-1.25 Fair  
1.26-1.34 Passable  
1.35-1.45 Poor  
1.46-1.59 Very poor  
>1.60 Very, very poor 
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g) Compatibility Studies: 
IR spectra matching approach was used for detection of any possible chemical 
interaction between drug and polymer. A physical mixture (1:1) of drug and polymer 
was prepared and mixed with the suitable quantity of potassium bromide. About 100mg 
of mixture was compressed to form a transparent pellet using a hydraulic press at 6tons 
pressure .It was scanned from 4000 to 400 cm-1 in FTIR spectrometer. The IR spectrum 
of the physical mixture was compared with those of pure drug and polymers and 
matching was done to detect any appearance or disappearance of peaks. The IR 
spectrums of the sample and of the Glibenclamide working/reference standard in the 
range of 4000 cm-1 to 400 cm-1 were taken by preparing dispersion in dry potassium 
bromide under the same operational conditions mentioned above 
 
6. Compression of Liquisolid Tablet 
Weigh accurately about 250 mg (according to Table : 12) of  the mixture blend and fed 
into the die of single punch tablet press and compressed at 1.5N compression force using 
8mm concave punches. 
 
7. Evaluation of Tablet 
 a) Weight variation test: 
20 tablets were selected at random and weighed individually. The average weight of each 
batch of tablet was calculated. Individual weights of the tablets were compared with the 
average weight. Since the tablet weighed around 250mg, IP specifies that the tablets pass 
the test if not more than two of the individual weights deviate from the average weight 
by more than 7.5%. 
 
Table 9:   Weight variation limit as per IP 
Percentage deviation allowed under weight variation test 
Average weight of tablet Percentage deviation 
≤ 80mg 10% 
80-250mg 7.5% 
≥ 250mg 5% 
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b) Thickness and Hardness 
Thickness was measured during tablet compression using Vernier caliper. Hardness of 
the tablet was measured by Pfizer tablet hardness tester. The tablets were held vertically 
in between the jaws which were pressed with hand until the tablet broken. The reading 
was noted from the needle of pressure dial which may be expressed in kilograms. 
 
c) Friability 
This is performed to evaluate the ability of tablet to withstand abrasions. Ten tablets 
were weighed and placed in the tumbling chamber of Roche friabilator which rotated for 
100 revolutions at a speed of 25 rpm . The tablets were again weighed and the loss in 
weight indicated the friability. Friability value should not exceed 1 % according to IP 
specification. 
  
              A-B                                                                    
    % Friability =                        ....................... (9) 
     B 
 
Where A=Initial weight of tablet 
 B=Weight of tablet after 100 revolution. 
 
d) Assay of tablet. 
Ten tablets were randomly weighed and crushed. Calculated the average weight and 
taken the powder equivalent to 10 mg of Glibenclamide base in a 100 ml volumetric 
flask. Add few ml methanol and sonicated for 10 minute. Then volume made up to 100 
ml with phosphate buffer (pH 7.4).The 1mL of resultant solution diluted to 100mL with 
phosphate buffer (pH 7.4) and the absorbance was measured using UV 
spectrophotometer at 227nm 
62
. 
 
e) Invitro-Dissolution studies 
The Glibenclamide release from different formulations was determined using a USP 
XXIII paddle apparatus 2 under sink condition. The dissolution medium was 900 ml 
phosphate buffer (pH 7.4) at 37 ± 0.2 °C; paddle speed 50 rpm, to simulate in vivo 
conditions. All experiments were done in triplicate and average values were taken. The 
formulation prepared was subjected to dissolution tests for 1 hr. Sample (10 ml) was 
withdrawn at predetermined time intervals, filtered through Whatmann filter paper and 
61 
 
replaced by an equal volume of dissolution medium. Drug content in the dissolution 
sample was determined by UV spectrophotometer at 227nm. 
 
Dissolution Condition: 
Apparatus  : USP XX111 paddle apparatus 2. 
RPM   : 50 
Medium  : Phosphate buffer (pH 7.4) 
Sampling Interval : Every 10 minute.  
Sampling Volume : 10ml. 
Study Period  : 1 hr 
 
f) Differential scanning calorimetry (DSC) 
DSC (Q20 V24.2) was performed using assess thermotropic properties and thermal 
behaviors of Glibenclamide and of liquisolid system prepared. Samples (3-5mg) were 
placed in aluminum pans and lids at constant heating range of 10 °C/min, covering 
temperature range 30 to 300 °C. Nitrogen was used as purge gas through DSC cell. 
g) Xray powder diffraction analysis 
 
Crystallinity of the drug and the samples was determined using the XRD-6000 
diffractometer with copper target. The conditions were: 40 kV voltages; 30 mA current. 
The samples were loaded on to the diffractometer and scanned over a range of   2θ 
values from 10 to 80 
0
 at a scan rate of 10.00 
0
 /min. 
 
 
8. STABILITY STUDIES:  
The prepared formulations which showed best in vitro results was selected and kept for 
stability testing for 90 days. The tablets were kept at 40± 2°C/ 75%±5%RH in a stability 
chamber and samples were withdrawn at initial, 30
 th
 , 60 
th
 and 90
th
 day and evaluated 
for drug content, disintegration , dissolution  study.  
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8. RESULTS AND DISCUSSION 
1. CALIBRATION CURVE OF GLIBENCLAMIDE  
 
A calibration curve for Glibenclamide was constructed in phosphate buffer pH 7.4 by 
scanning the diluted drug solution at 227 nm using UV spectrophotometer. The linearity 
of the calibration curve was found to be in the range of 1-10µg/ml. A regression 
coefficient value of 0.998 was noticed for Glibenclamide. 
 
 
Table 10:  Calibration Data of Glibenclamide 
 
 
Fig 3 : 
Calibration curve of Glibenclamide in Phoshate buffer  
pH 7.4 at   227nm 
 
 
 
2. SOLUBILITY STUDIES 
y = 0,059x + 0,002
R² = 0,998
0
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Linear (abs)
Concentration (µg/ml) Absorbance 
0 0 
2 0.1354 
4 0.2328 
6 0.3585 
8 0.4736 
10 0.6076 
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The solubility of Glibenclamide in different solvents were studied to select the suitable 
solvent to be used in the formulation. The results obtained were given in Table.11. 
Glibenclamide showed a maximum solubility of 2.7407%w/w in propylene glycol (PG) 
followed by 1.837%w/w in Tween 80 and 0.5919%w/w in PEG 400.  Maximum 
solubility of the drug is needed for preparing liquisolid compacts, as higher the 
solubility, the more the drug will be dissolved in the vehicle prior to the adsorption onto 
the carrier particles. As Propylene glycol showed greater solubility of the drug than the 
other two solvents, it was selected as the suitable solvent for preparing Glibenclamide 
liquisolid compacts in this study.  
 
Table 11: Solubility of Glibenclamide in different solvents 
 
Solvents Solubility (%w/w) 
Propylene Glycol 2.7407 
PEG 400 0.5919 
Tween 80 1.837 
Distilled Water 0.004 
                  
3. APPLICATION OF NEW MATHEMATICAL MODEL FOR DESIGN OF 
     LIQUISOLID SYSTEM 
 
The liquisolid technique as suggested by Spireas et al
36
, states that the drug dissolved in 
a liquid vehicle is incorporated into carrier and coating materials having porous structure 
and closely matted fibres in its interior, is a phenomenon of both adsorption and 
absorption. Coating materials like Aerosil PH 102 have high adsorptive capacity and 
greater surface area and thus gives the liquisolid systems the desirable flow and 
compaction properties. 
 
To calculate the required quantities of carrier and coating materials, the flowable liquid-
retention potentials (Φ values) of the powder materials were used. Spireas et al36 has 
given a mathematical model equation for Avicel PH 102 and Aerosil 200 in propylene 
glycol according to values of Phi (Φ) which is given below. 
 
Lf = 0.16 + 3.31 (1 / R)................. (10) 
Where 0.16 is the Φ value for Avicel PH 102 and 3.31 for Aerosil 200. Based on this  
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equation, Liquid Load factor (Lf) was calculated by using different R values for all the 
formulations.  
 
 
The quantity of carrier material (Q) required and the quantity of coating material (q) was 
calculated by using the following equation; 
 
Amount of carrier material required (Q) = W/Lf.................. (11) 
Amount of coating material required (q) = Q/R..................... (12) 
 
where, W is the weight of the liquid  medication, Lf is the liquid load factor, R is the 
coating and carrier material ratio. The formulation table according the above calculations 
is shown in Table 12. 
 
Table 12 Formulation chart 
 
Formulation 
Drug 
conc 
(%w/w) 
R Lf 
Q 
(mg) 
q 
(mg) 
Fm 
LS-1  
5 
 
10 0.491 213.85 21.38 0.54814 
LS-2 20 0.325 323.07 16.15 0.54814 
LS-3 30 0.270 388.88 12.96 0.54814 
LS-4 
 
10 
10 0.491 224.03 22.40 0.27407 
LS-5 20 0.325 338.46 16.92 0.27407 
LS-6 30 0.270 407.407 13.58 0.27407 
LS-7 
 
15 
10 0.491 234.21 23.42 0.1827 
LS-8 20 0.325 353.84 17.69 0.1827 
LS-9 30 0.270 425.93 14.19 0.1827 
LS-10 
 
20 
10 0.491 244.39 24.43 0.13703 
LS-11 20 0.325 369.23 18.46 0.13703 
LS-12 30 0.270 444.44 14.81 0.13703 
R – carrier: coating  ratio , Q –weight of carrier  , q - weight of coating material, Fm – 
fraction of molecularly dispersed drug. 
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4. EVALUATION OF FLOWABILITY AND COMPRESSIBILITY OF 
       LIQUISOLID POWDERS 
 
Powder flow properties are crucial in handling and processing operations such as flow 
from hoppers, mixing and compression. The flow properties of the liquisolid system 
were influenced by physical, mechanical as well as environmental factors. The powder 
flowability can be determined by evaluating parameters such as the compressibility or 
Carr‟s index, Hausner‟s ratio and the Angle of repose. 
 
As a general guide, powders with angles of repose greater than 50° have unsatisfactory 
flow properties, whereas minimum angles close to 25° correspond to very good flow 
properties 
63
. Table (13) revealed that all the tested liquisolid systems had a satisfactory 
flow according to the obtained results of measuring the angle of repose for each 
liquisolid system. The range was from 30.13 to 37.78˚. The prepared Glibenclamide 
liquisolid systems can be arranged in ascending order, regarding the angle of repose 
measurements as follows: LS-12< LS-4< LS-11< LS-10< LS-6< LS-2< LS-5< LS-8< 
LS-1 < LS-9< LS- 3< LS-7. 
 
The bulk and tapped densities for Glibenclamide liquisolid powders were illustrated in 
Table  (13) , the mean densities of  liquisolid powders were found to be from 0.285 to 
0.419 g/cm
3
 for bulk density and from 0.385 to 0.511 g/cm
3
 for tapped density. 
 
The powder has a good flowability, when the Hausner ratio is lower than 1.2, while it 
indicates poor flow when the value exceeds 1.2. It was showed that powders with 
interparticle friction, such as coarse spheres, had ratios of approximately 1.2, whereas 
more cohesive, less free-flowing powders such as flakes have Hausner ratios greater than 
1.6.  
 
Compressibility is indirectly related to the relative flow rate, cohesiveness, and particle 
size of a powder. A compressible material will be less flowable, and powders with 
compressibility values greater than 20-21 % have been found to exhibit poor flow 
properties 
64
. The results obtained for evaluation of compressibility index and Hausner‟s 
ratio is given in Table 13. 
 
Hausner ratio and Carr‟s index were calculated from the density values. These results 
revealed that LS-9, LS-10, LS-11 and LS-12 had Hausner ratio of 1.16, 1.19, 1.16 and 
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1.18, respectively, which were less than 1.2 and is an indication for good flowability and 
the rest formulae had low flowability because it had Hausner ratio more than 1.2. 
Formulae LS 3 and LS 5 in addition to LS- 9 to LS-12 had Carr‟s index values of less 
than 21% which supports the fact that these formulations have good flow and 
compaction properties. 
 Table 13:  Precompression studies  
 
FORMULATIONS 
ANGLE 
OF 
REPOSE 
DENSITIES (g/cm
3 
) HAUSNERS 
RATIO 
CARR’S 
INDEX BULK TAP 
LS-1 36.53 0.298 0.385 1.29 22.5 
LS-2 34.21 0.312 0.403 1.31 22.6 
LS-3 34.13 0.364 0.453 1.24 19.6 
LS-4 32.59 0.285 0.425 1.49 32.9 
LS-5 34.95 0.416 0.511 1.22 18.6 
LS-6 33.68 0.321 0.496 1.54 35.2 
LS-7 37.78 0.357 0.473 1.32 24.52 
LS-8 35.17 0.364 0.463 1.27 21.38 
LS-9 36.62 0.419 0.490 1.16 14.48 
LS-10 33.47 0.395 0.473 1.19 16.4 
LS-11 33.18 0.412 0.482 1.16 14.52 
LS-12 30.13 0.407 0.483 1.18 15.73 
CT 32.65 0.423 0.471 1.11 10.19 
LS-Liquisolid tablet, CT – conventional tablet 
 
5. COMPRESSION OF TABLET: 
The liquisolid tablets were prepared by direct compression technique. The target weight 
of the prepared tablet was 250mg.  The desired hardness is between 3-5kg/cm
2
. All the 
tablets were found to be uniform in size and shape and no processing problems were 
encountered during compression process. Similarly conventional tablet of pure drug was 
also prepared by direct compression technique.  
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6. EVALUATION OF POST COMPRESSION PARAMETERS: 
 
The mean hardness of the tablets ranged from 3.5 -5 kg/cm
2 
,
 
the mean of the hardness 
values were shown in Table (14). It was found that there is a relationship between liquid 
load factor and the hardness of the tablets. The Lf was inversely proportional to the 
hardness of the tablets ie when the Lf increased the hardness of the tablets will decrease. 
Formula LS-1, LS-5 were having Lf 0.491 and 0.325 and the mean hardness of them was 
4 and 5. Also formula LS-4 and LS- were having Lf 0.491 and 0.270, and the mean 
hardness of them was 3.5and 5. And this finding was confirmed by third example where 
formula LS-10 and LS-12 were having Lf 0.491 and 0.270, and the mean hardness of 
them was 3 and 5 respectively. This can be explained by the fact that increasing Lf of the 
formula increases the amount of solvent used and decreases the amount of powder 
excipient and this subsequently, decrease the hardness of the tablets. 
 
LS-6 showed the best result of friability test regarding to the loss of weight (0.006 %), 
while LS-5 had the largest weight loss (0.015%). 
 
The disintegration time for the prepared Glibenclamide liquisolid tablets was shown in 
table (14). It was found that the mean of the disintegration times for all the investigated 
tablets were less than 16 minutes, which meets the Pharmacopoeial requirements. LS – 3 
was found to be the fastest formula to be disintegrated (1.46 minutes) followed by LS-2, 
LS-6 and LS-5with disintegration times of 1.50, 2.10 and 2.45 minutes respectively. The 
slowest disintegration time was observed with the formula LS -10, which took 12.30 
minutes to disintegrate. 
 
The data obtained from the disintegration test suggested that the powder excipient ratio 
(R) has an influence on the disintegration time of the liquisolid compacts. The powder 
excipient ratio (R) was found to be inversely proportional to the disintegration time of 
the tablets. Formula LS-1 LS-2 and LS-3were having the R values 10, 20 and 30, and 
their mean disintegration time were 3.20, 1.50 and 1.46 minutes respectively. This 
phenomenon can be explained by the fact that, increasing the R value leads to high 
carrier material content in the tablet, in this case microcrystalline cellulose (Avicel PH 
102) which functions as a swellable disintegrant. Also, the highly hydrophilic 
characteristic of microcrystalline cellulose could increase the wetting of Glibenclamide 
and this subsequently, lead the tablet to be disintegrated quickly 
65
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It was clear from Table 14 that all the investigated liquisolid tablets complied with the 
pharmacopoeial requirements with regard to their content uniformity, which was found 
to lie within the range of 96.12 to 101.2 %. 
 
Table 14:  Post compression parameters 
 
Form 
ulations 
Average 
Weight 
(mg) 
Hardness 
(kg/cm
2
) 
Friability 
(%) 
Disintegration 
time (min) 
Content 
uniformity 
(%) 
LS-1 253±3 4 0.007 3.20 96.5 
LS-2 251±9 4.5 0.009 1.50 96.7 
LS-3 250±5 5 0.013 1.46 99.3 
LS-4 248±1 3.5 0.015 3.45 98.6 
LS-5 246±2 5 0.008 2.45 99.7 
LS-6 253±4 5 0.006 2.10 97.3 
LS-7 250±1 3.5 0.019 4.21 101.2 
LS-8 249±5 4 0.007 4.57 98.5 
LS-9 250±2 5 0.014 5.32 99.1 
LS-10 250±6 3 0.017 12.30 96.12 
LS-11 254±4 4 0.006 9.40 96.6 
LS-12 255±2 5 0.008 7.25 98.7 
CT 250±1 3.5 0.015 20.10 97.2 
MT 10±5 4 0.009 18.15 96.9 
 
LS-Liquisolid tablet, CT- Conventional tablet, MT- Marketed tablet 
 
7. COMPATIBILITY STUDIES: 
The spectrum obtained after the analysis is shown in Figs.4-7. The spectrum of the 
standard and the samples were then superimposed to find out any possible interactions 
between the drug and the polymers. All the characteristic peaks of Glibenclamide 
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mentioned in table (15) were also found in the spectrum formulations. The results 
suggests that the drug is intact in the formulations and there is no interaction found 
between the drug and the excipients. 
          
                        Table 15: Characteristic peaks of Glibenclamide 
 
 
Serial 
number 
Wavelength Specification 
1. 3315 cm
-1
 Amide NH stretching vibration 
2. 1745cm
-1
 Amide C=O stretching 
3. 1617cm
-1
 Amide NH bending 
4. 1342cm
-1
 SO2 stretching 
5. 1430cm
-1
 CH2    bending vibration 
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FIGURE 4:IR OF GLIBENCLAMIDE 
 
 
 
 
FIGURE 5: IR OF MCC 
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FIGURE 6 :IR OF AEROSIL 
 
 
 
 
                                                            
FIGURE 7      IR OF LIQUISOLID FORMULATION 
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8. DIFFERENTIAL SCANNING CALORIMETRY (DSC) 
DSC studies were carried out to determine the interaction between drug and excipients in 
prepared liquisolid formulation and also to detect changes in the drug crystallinity. DSC 
thermograms of Glibenclamide and final liquisolid formulation system were represented 
in Figure 8 and 9. The DSC thermogram of pure glibenclamide (Fig. 8) gave a sharp 
characteristic peak at temperature range        177.12°C corresponding to its melting 
temperature (Tm). This shows that Glibenclamide used was in pure form.  The DSC 
thermogram of liquisolid system (Fig. 9) does not feature a sharp characteristic peak of 
Glibenclamide at 177.12°C which ensures the formation of drug solution in liquisolid 
formulation and thus confirms that the drug was molecularly dispersed in liquisolid 
system. Also there is a broad peak at 86.85˚C which corresponds to the evaporation of 
water associated with Avicel PH 102 particles. 
 
 
 
 
 
FIGURE 8: DSC OF GLIBENCLAMIDE 
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FIGURE 9: DSC OF LIQUISOLID SYSTEM 
 
 
 
 
9. X-RAY POWDER DIFFRACTION (XRPD) 
Polymorphic changes in the drug are important since they might affect the dissolution 
rate and in turn bioavailability. So, it was necessary to study the polymorphic changes of 
Glibenclamide in liquisolid compacts. Figs.10 and 11 shows the XRPD of pure drug and 
the liquisolid system Glibenclamide has sharp peaks at 18.84, 20.85, 19.40 and 22.94 at 
2θ. Avicel PH 102 has a sharp diffraction peak at 23.29 at 2θ while the liquisolid powder 
had a sharp diffraction peak at 22.37 at 2θ which is evidence that Avicel PH 102 remains 
in its crystalline state. The absence of characteristic peaks of Glibenclamide in the 
liquisolid system shows the conversion of drug to an amorphous or solubilized form. The 
absence of crystallinity in the liquisolid system is due to the solubilization of drug in the 
liquid vehicle. 
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FIGURE 10:X-RAY DIFFRACTOGRAM OF GLIBENCLAMIDE 
 
 
 
 
 
 
FIGURE 11: X-RAY DIFFRACTOGRAM OF LIQUISOLID SYSTEM 
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10. IN VITRO DISSOLUTION STUDY 
 
Figs 12-16 show the dissolution profile of 12 formulations, conventional tablet of pure 
drug and marketed tablet. Liquisolid compacts displayed more distinct in-vitro release 
characteristics than the conventional and marketed drug. Among all,   LS-3 showed 
higher release rate (91.35%) at the end of the 60
th
 min. Conventional tablet and marketed 
tablet showed only 35.73% and 33.22% cumulative release. It was confirmed that at 10 
min LS-3 had the highest drug release 57.73% compared with 15.75% for the 
conventional tablet. Since the liquisolid compacts contain a solution of the drug in non 
volatile vehicle used for preparation of the liquisolid compacts, the drug surface 
available for dissolution is tremendously increased. In essence, after disintegration, the 
liquisolid primary particles suspended in the dissolving medium contain the drug in a 
molecularly dispersed state, whereas the directly compressed compacts are merely 
exposed micronized drug particles. Therefore, in the case of liquisolid compacts, the 
surface area of drug available for dissolution is much greater than that of the directly 
compressed compacts. 
 
According to Noyes and Whitney, the drug dissolution rate (DR) is directly proportional 
not only to the concentration gradient (Cs-C) of the drug in the stagnant diffusion layer, 
but also to its surface area (S) available for dissolution. Moreover, since all dissolution 
tests for both Glibenclamide preparations were carried out at a constant rotational paddle 
speed (50 r/min) and identical dissolving media, it is assumed that the thickness (h) of 
the stagnant diffusion layer and the diffusion coefficient (D) of the drug molecules 
transported through it remain almost identical under each set of dissolution conditions. 
Therefore, the significantly increased surface area of the molecularly dispersed 
Glibenclamide in the liquisolid compacts may be principally responsible for their higher 
dissolution rates. The consistent and higher dissolution rate displayed by liquisolid 
compacts will improve the absorption of drug from the GI tract. 
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Table 16 Percentage of drug release from liquisolid tablets, conventional and 
marketed tablets 
  
Formulation 
Time(hrs) 
10 20 30 40 50 60 
LS-1 48.56 59.73 65.19 72.32 81.92 85.97 
LS-2 52.92 61.43 67.66 76.96 83.64 88.62 
LS-3 57.73 65.94 69.17 78.53 86.72 91.35 
LS-4 25.96 37.52 48.39 59.38 70.37 77.47 
LS-5 27.12 40.35 51.55 69.75 78.41 80.34 
LS-6 29.19 42.72 55.69 71.33 80.53 83.68 
LS-7 20.79 32.13 40.59 54.24 63.95 71.84 
LS-8 21.98 35.63 43.74 56.19 67.33 74.57 
LS-9 25.96 39.52 48.42 59.37 70.69 76.38 
LS-10 12.13 27.95 32.31 41.82 53.73 65.31 
LS-11 10.31 29.33 37.53 42.29 57.54 67.95 
LS-12 14.73 32.64 41.30 48.73 60.14 69.77 
PURE 
DRUG 
15.75 27.50 31.91 33.32 35.20 35.73 
MARKETED 17.52 26.06 27.21 30.28 31.14 33.22 
     LS – Liquisolid tablet 
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Figure 12: Dissolution profile of formulations with 5 % drug concentration 
 
 
 
 
 
Figure 13: Dissolution profile of formulations with 10% drug concentration 
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Figure 14: Dissolution profile of formulations with 15% drug concentartion 
 
 
 
 
Figure 15: Dissolution profile of formulations with 20% drug concentartion 
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Figure 16: Dissolution profile of best formulation (LS-3) pure drug and marketed 
tablet 
 
 
a. Effect of drug concentration on release rate: 
Figs: 17 show that formulations with smaller drug concentration (5%w/w) have a higher 
dissolution than higher drug concentration (20%w/w). 
 
 
Figure 17: Dissolution profile of formulations with excipient ratio 30 and different 
drug concentration. 
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This can be explained by the dissolved drug in the liquid medication as follows: 
 FM=CL/CD          ..................... (13) 
 
where FM is the fraction of molecularly dispersed or dissolved drug in liquid medication 
of the prepared liquisolid formulation, CL is the saturation solubility of Glibenclamide in 
the liquid vehicle and CD is the drug concentration in the liquid medication. According to 
Spireas et al, FM value cannot exceed unity. The saturation solubility of Glibencamide in 
PG is 2.7407%w/w (Table 11 ), by applying Eq. (13), it can be calculated that 52.4% of 
the drug was solubilised in LS-3 , 27.40% of Glibenclamide was solubilised in LS-6, 
18.27% of Glibenclamide was solubilised in LS-9 and 13.703%w/w of Glibenclamide in 
LS-12. The higher the drug concentration in a liquisolid formulation, the lower will be 
the amount of drug solubilised in the liquid vehicle. Apparently, LS-3 which has 52.41% 
of drug available in solubilised form promote higher dissolution rate than LS-6, LS-9 and 
LS-12. It was proven that FM is directly proportional to the drug dissolution rate. The 
FM values of such liquisolid formulations were listed in Table (12). Another explanation 
for this phenomenon is that high concentration of the drug could precipitate within the 
silica (Aerosil) pores; thus, drug dissolution rate would be reduced. The potential of 
Glibenclamide to precipitate within the silica pores is depending on the solubility of the 
drug in the solvent, the degree of saturation of the drug solution or the interactions 
between drug and excipients . 
 
a. Effect of powder excipient ratio (R) on drug release: 
From the obtained results, it was clear that there exists a relationship between the powder 
excipient ratio and the invitro release of Glibenclamide from liquisolid tablets. The 
powder excipient ratio was directly proportional to the in vitro release i.e., when the 
powder excipient ratio increased, the release will increase. This finding was confirmed 
from the following results. Formulae LS-1, LS-2, and LS-3 were having R value 10, 20, 
30, and the cumulative percent released were 85.97, 88.62, and 91.35%, respectively. 
Also, formulae LS-4, LS-5, and LS-6 were having R value equal to 10, 20, 30, and the 
cumulative percent released of them were 77.47, 80.34, and 83.68%, respectively. This 
may be attributed to the high microcrystalline cellulose content where Avicel PH 102 
functions as a swellable disintegrant. In addition, the highly hydrophilic characteristic of 
microcrystalline cellulose could increase the wetting of Glibenclamide and enhance its 
dissolution. 
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11. STABILITY STUDIES: 
The purpose of stability testing is to provide evidence on how the quality of a drug 
substance or drug product varies with time under the influence of a variety of 
environmental factors such as temperature, humidity, and light, and to establish a re-test 
period for the drug substance or a shelf life for the drug product and recommended 
storage conditions.  Here the tablets were loaded at accelerated condition at 
40
0
C±2
0
C/75% RH±5%RH in a stability chamber. Samples were withdrawn at initial, 
30, 60, and 90 days and evaluated for drug content, dissolution and disintegration time. 
The result showed that storage at 40 ºC had no effect on the drug content, disintegration 
time and dissolution time. This indicates that the technology is a promising technique to 
enhance the release rate without having any physical stability issues. 
 
                 Table .17 Stability study of Glibenclamide 
Condition 40ºC 
Sl.No Parameters 
L3 
Initial 30
th
 day 60
th
  day 90
th
 day 
1. Drug content (%) 99.3 98.9 98.7 99.4 
2. Disintegration time (min) 1.46 1.55 1.4 1.5 
3. 
Dissolution (%CR in 1 hr) 
91.35 90.45 90.85 91.22 
 
CR – cumulative release 
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9. SUMMARY 
The present study was aimed at preparing Liquisolid compacts of Glibenclamide to 
enhance its dissolution rate. Glibenclamide is a poorly water soluble antidiabetic drug 
which belongs to BCS class II drugs. Hence it will be beneficial to increase its 
dissolution rate in order to improve its bioavailability by Liquisolid technique. 
Formulation 
In the preparation of liquisolid compacts, a suitable non volatile solvent having sufficient 
solubility for the drug should be chosen followed by a suitable carrier and coating 
materials. In this study, propylene glycol was selected as the liquid vehicle as it showed 
enhanced solubility than tween 80 and PEG 400. Avicel and aerosil were chosen as 
carrier &coating material. CCS was chosen as the super disintegrant. A total of 12 
formulations were made using four different concentrations of drug (5,10,15 & 20% 
w/w) at three different R values i.e 10, 20 & 30. 
Preformulation Studies 
Preformulation studies of the prepared liquisolid powder blend of all the 12 formulations 
were performed. Parameters like angle of repose, bulk density, tapped density, 
compressibility index, Hausner‟s ratio and swelling studies for the polymers were 
studied. The results obtained from the above studies showed that the prepared blend was 
having satisfactory fluidity and compressibility and  hence can be processed into tablets 
by direct compression method.  
Compression of Tablets 
Tablets were compressed by direct compression method using Rimek Tablet punching 
machine to a target weight of about 250 mg. All the tablets prepared were having 
uniform size and thickness with a hardness of about 3.5-5kg/cm. There were no 
processing problems encountered during the compression process.  
Evaluation of Tablets 
The compressed tablets were then evaluated for various tests like hardness, weight 
variation, content uniformity, friability etc as per the method given by Indian 
Pharmacopeia All the 12 formulations passed in these tests with values within the limit 
prescribed by the IP. IR studies was also done to check  the interaction between drug  
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and excipients and the result showed that the drug is intact and compatable with the 
excipients.   
Differential Scanning Calorimetry (DSC) 
DSC thermogram of Glibenclamide showed a sharp peak at 177.12 °C which 
corresponds to its melting point. This shows that the drug is in pure form. DSC 
thermogram of formulation does not showed any peak and hence ensures formation of 
drug solution in liquisolid formulation. This confirms that drug was molecularly 
dispersed in liquisolid system. 
X- Ray powder diffraction (XRPD) 
Sharp distinct characteristic peaks at 2θ diffraction angles for Glibenclamide at 18.84, 
20.85, and 19.40 indicated its crystalline state. X-ray diffractogram of liquisolid powder 
showed absence of these distinct peaks. Hence absence of specific peaks in liquisolid 
system revealed that Glibenclamide has been completely converted to molecular form or 
solubilised form. This lack of crystallinity in the formulation might be due to 
solubilization of drug in liquid vehicle which was absorbed into carrier material and 
adsorbed onto carrier and coating materials. 
In Vitro Drug Release Studies 
The in vitro drug release studies of all the formulations were studied using USP Type II 
Paddle apparatus with phosphate buffer pH 7.4 as the dissolution medium. The study was 
performed for 1h and an average of three determinations was reported.  From the 
observed result it was noted that formulation with less drug concentration and high R 
value shown higher release rate. . The lower the drug concentration in a liquisolid 
formulation more will be the amount of drug solubilised in the liquid vehicle. Also, the 
highly hydrophilic characteristic of microcrystalline cellulose could increase the wetting 
of Glibenclamide and enhance its dissolution. Although all formulation shown good 
release rate than conventional and marketed tablet. LS-3 was chosen as the best 
formulation due to its higher percentage release. 
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10. CONCLUSION 
 
 
Solubility is one of the major factors which affects the in vivo performance of the drug. 
Poorly soluble drugs throw a stiff challenge to the formulation scientists in producing a 
dosage form for such drugs with satisfactory dissolution profile. Among the various 
mechanisms used for improving the solubility and thereby the dissolution of these drugs, 
liquisolid technique is gaining much attention and importance in recent years. The 
availability of drug in the solubilised form and increase in the wettability of the powders 
by the dissolution media were some of the proposed mechanisms to explain the enhanced 
dissolution  rate of poorly soluble drugs from such formulations. 
 
Hence, in this study, liquisolid technique was chosen to enhance the dissolution 
properties of Glibenclamide. The Glibenclamide liquisolid compacts were prepared by 
using propylene glycol as the non volatile liquid vehicle. Avicel PH 102 and Aerosil 200 
were used as the carrier and coating material, respectively. The flow properties of 
Glibenclamide liquisolid compacts showed an acceptable flowability. The hardness, 
friability, weight variation and disintegration tests were within acceptable limits. The in 
vitro dissolution study confirmed enhanced drug release from liquisolid compacts 
compared with conventional and marketed tablet. XRPD studies showed complete 
inhibition of crystallinity in the Glibenclamide liquisolid compacts suggesting that the 
drug has been transformed into amorphous form having more solubility than the parent 
drug. The DSC study also supported the findings of  XRPD analysis and confirmed the 
absence of any interaction between the drug and excipients used in the preparation of 
Glibenclamide liquisolid compacts. The liquisolid tablets having drug concentration of 
5%w/w  (LS-3) with Lf value of 0.270 and R value of 30, was chosen as  best 
formulation among the twelve batches, in terms of faster disintegration time, superior 
dissolution profile and acceptable tablet properties. 
 
This research work has produced encouraging results in terms of increasing the in vitro 
dissolution of poorly soluble drugs such as glibenclamide using liquisolid technology 
and we expect a good correlation between the in vitro and in vivo performance of the 
formulations. The technique being simple and effective can also be extended to other 
poorly soluble drugs. The in vivo performance of the liquisolid compacts has to be 
studied using animal models to claim a complete success in the development of these 
formulations. 
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